2101625-18-5: Tetraxetan Related Compound A

2101625-18-5: Tetraxetan Related Compound A

Tetraxetan Related Compound A (CAS No: 2101625-18-5) Or 2,2?,2?-[10-(2-Ethoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetic acid, Tetraxetan is used as a complexing agent, Its complexes have medical applications as contrast agents and cancer treatments.

Additional information on CAS 2101625-18-5

Catalogue No.

VE008438
CAS No.

2101625-18-5
Molecular Formula

C18H32N4O8
Molecular Weight

432.47 g/mol
Parent drug

Tetraxetan
IUPAC Name

2, 2′, 2″-[10-(2-Ethoxy-2-oxoethyl)-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7-triyl]triacetic acid
Synonyms

N/A
References

Sci-Hub, Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer : A phase 1 trial, 10.1002/cncr.27592. (2012). Retrieved December 27, 2021, from Sci-hub.ee website: https://sci-hub.ee/10.1002/cncr.27592
Status

In-stock

[rfq_list]

Login first to add product to RFQ List

Request a quote

2101625-18-5: Tetraxetan Related Compound A

2101625-18-5: Tetraxetan Related Compound A
Catalogue No.

VE008438
CAS No.

2101625-18-5
Molecular Formula

C18H32N4O8
Molecular Weight

432.47 g/mol
Parent drug

Tetraxetan
IUPAC Name

2, 2′, 2″-[10-(2-Ethoxy-2-oxoethyl)-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7-triyl]triacetic acid
Synonyms

N/A
References

Sci-Hub, Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer : A phase 1 trial, 10.1002/cncr.27592. (2012). Retrieved December 27, 2021, from Sci-hub.ee website: https://sci-hub.ee/10.1002/cncr.27592
Status

In-stock
ListName

Tetraxetan Related Compound A
Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url
 
Hidden